62.65
0.95 (1.54%)
Penutupan Terdahulu | 61.70 |
Buka | 63.33 |
Jumlah Dagangan | 923,580 |
Purata Dagangan (3B) | 1,876,150 |
Modal Pasaran | 2,102,627,968 |
Harga / Pendapatan (P/E TTM) | 67.37 |
Harga / Pendapatan (P/E Ke hadapan) | 58.14 |
Harga / Jualan (P/S) | 5.96 |
Harga / Buku (P/B) | 11.05 |
Julat 52 Minggu | |
Tarikh Pendapatan | 24 Feb 2025 - 28 Feb 2025 |
Margin Keuntungan | 8.14% |
Margin Operasi (TTM) | 3.61% |
EPS Cair (TTM) | 0.930 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 63.70% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 246.83% |
Nisbah Semasa (MRQ) | 8.20 |
Aliran Tunai Operasi (OCF TTM) | 37.44 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -142.59 M |
Pulangan Atas Aset (ROA TTM) | 2.84% |
Pulangan Atas Ekuiti (ROE TTM) | 19.41% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Devices (US) | Bercampur | Bercampur |
Medical Devices (Global) | Bercampur | Bercampur | |
Stok | TransMedics Group, Inc. | Menurun | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 1.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 4.5 |
Purata Bergerak Teknikal | -1.0 |
Osilator Teknikal | -2.0 |
Purata | 0.63 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
Sektor | Healthcare |
Industri | Medical Devices |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 3.21% |
% Dimiliki oleh Institusi | 113.48% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 125.00 (Oppenheimer, 99.52%) | Beli |
Median | 109.00 (73.98%) | |
Rendah | 75.00 (JP Morgan, 19.71%) | Pegang |
Purata | 106.14 (69.42%) | |
Jumlah | 5 Beli, 2 Pegang | |
Harga Purata @ Panggilan | 72.29 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
JP Morgan | 17 Dec 2024 | 75.00 (19.71%) | Pegang | 65.71 |
29 Oct 2024 | 116.00 (85.16%) | Beli | 88.50 | |
Baird | 11 Dec 2024 | 120.00 (91.54%) | Beli | 67.36 |
29 Oct 2024 | 150.00 (139.43%) | Beli | 88.50 | |
Piper Sandler | 11 Dec 2024 | 90.00 (43.66%) | Beli | 67.36 |
20 Nov 2024 | 110.00 (75.58%) | Beli | 77.20 | |
Oppenheimer | 03 Dec 2024 | 125.00 (99.52%) | Beli | 71.44 |
29 Oct 2024 | 125.00 (99.52%) | Beli | 88.50 | |
Needham | 22 Nov 2024 | 109.00 (73.98%) | Pegang | 76.04 |
29 Oct 2024 | 109.00 (73.98%) | Beli | 88.50 | |
Canaccord Genuity | 20 Nov 2024 | 104.00 (66.00%) | Beli | 77.20 |
29 Oct 2024 | 109.00 (73.98%) | Beli | 88.50 | |
TD Cowen | 18 Nov 2024 | 120.00 (91.54%) | Beli | 80.93 |
Papar semua |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
23 Dec 2024 | Pengumuman | TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
12 Dec 2024 | Pengumuman | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
02 Dec 2024 | Pengumuman | TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook |
26 Nov 2024 | Pengumuman | TransMedics to Host Investor & Analyst Day on December 10, 2024 |
19 Nov 2024 | Pengumuman | TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference |
29 Oct 2024 | Pengumuman | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
28 Oct 2024 | Pengumuman | TransMedics Reports Third Quarter 2024 Financial Results |
15 Oct 2024 | Pengumuman | TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |